[16] Indeed, MCL-1 inhibitors are currently entering clinical trials to treat AML and multiple myeloma patients (Clinical trials—NCT02979366; NCT02675452; NCT02992483). The gene discussed is MCL1; the disease is acute myeloid leukemia.